María Villalba-Esparza

6PUBLICATIONS
61CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2026
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

|Jan 17, 2025
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.

Miguel Lopez de Rodas, Maria Villalba-Esparza, Miguel F Sanmamed

|Mar 06, 2021
Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling.

Álvaro López-Janeiro, Ignacio Ruz-Caracuel, Jorge L Ramón-Patino

|Dec 30, 2020
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.

Alvaro Teijeira, Saray Garasa, Maria C Ochoa

|Oct 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.

Iosune Baraibar, Marta Roman, María Rodríguez-Remírez

Pageof 1

Frequent Collaborators

2 joint publications

Iñaki Eguren-Santamaria

2 joint publications

Miguel F Sanmamed

2 joint publications

Raluca Alexandru

1 joint publications

Alvaro Teijeira